한글목차

Immunovant의 첫 번째 임상시험용 약물인 바토클리맙(IMVT-1401)은 신생아 Fc 수용체(FcRn)를 표적으로 하는 새로운 완전 인간형 단클론항체입니다. 비임상 및 임상시험에서 바토클리맙은 IgG 항체 수치를 낮추는 것으로 확인되었습니다. 고농도의 병원성 IgG 항체는 다양한 자가면역질환의 원동력이며, 결과적으로 이 제품 후보물질은 자가피하주사제로서 다양한 IgG 매개 자가면역질환을 치료할 수 있는 잠재력을 가지고 있습니다.

신생아 Fc 수용체(FcRn)는 IgG 항체와 결합하여 세포 내 수송을 유도하는 세포 수용체로, IgG 항체의 분해를 방지하는 데 매우 중요한 역할을 합니다. 따라서 FcRn을 표적으로 하는 항체로 FcRn을 억제하면 병원성 IgG 항체의 수치가 감소하는 것으로 나타났으며, IgG 매개 자가면역질환에 대한 다른 항FcRn 항체의 임상시험이 완료되어 유망한 결과를 보임에 따라 FcRn은 관련 질환을 치료하기 위한 중요한 치료 표적 치료하기 위한 치료적으로 중요한 의약학적 타겟이 될 수 있음을 시사하고 있습니다.

앞으로 몇 년동안 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 베체트병 안질환 시장 시나리오가 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 바토클리맙의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 안구 질환 치료제들이 바티클레맙과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 그레이브스 안질환 치료제 Batoclimab 시장에 대해 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 그레이브스 안질환에서의 바토클리맙 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 바토클리맙 시장 평가

• 그레이브스 안질환용 바토클리맙 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 그레이브스 안질환용 바토클리맙 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"Batoclimab Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about batoclimab for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the batoclimab for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the batoclimab for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the batoclimab market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.

Drug Summary:

Immunovant's first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection.

The neonatal Fc receptor (FcRn) is a cellular receptor that binds IgG antibodies and guides their transport through cells. FcRn plays a pivotal role in preventing the degradation of IgG antibodies. Therefore, inhibition of FcRn with an FcRn targeting antibody has been shown to reduce levels of pathogenic IgG antibodies. Completed clinical trials of other anti-FcRn antibodies in IgG-mediated autoimmune diseases have generated promising results, suggesting that FcRn is a therapeutically important pharmaceutical target to treat these relevant pathogenic conditions.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the batoclimab description, mechanism of action, dosage and administration, research and development activities in Graves' Ophthalmopathy.
• Elaborated details on batoclimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the batoclimab research and development activities in Graves' Ophthalmopathy across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around batoclimab.
• The report contains forecasted sales of batoclimab for Graves' Ophthalmopathy till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Graves' Ophthalmopathy.
• The report also features the SWOT analysis with analyst views for batoclimab in Graves' Ophthalmopathy.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Batoclimab Analytical Perspective by DelveInsight

• In-depth Batoclimab Market Assessment

This report provides a detailed market assessment of batoclimab for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• Batoclimab Clinical Assessment

The report provides the clinical trials information of batoclimab for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Graves' Ophthalmopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence batoclimab dominance.
• Other emerging products for Graves' Ophthalmopathy are expected to give tough market competition to batoclimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of batoclimab in Graves' Ophthalmopathy.
• Our in-depth analysis of the forecasted sales data of batoclimab from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the batoclimab in Graves' Ophthalmopathy.

Key Questions:

• What is the product type, route of administration and mechanism of action of batoclimab?
• What is the clinical trial status of the study related to batoclimab in Graves' Ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the batoclimab development?
• What are the key designations that have been granted to batoclimab for Graves' Ophthalmopathy?
• What is the forecasted market scenario of batoclimab for Graves' Ophthalmopathy?
• What are the forecasted sales of batoclimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to batoclimab for Graves' Ophthalmopathy?
• Which are the late-stage emerging therapies under development for the treatment of Graves' Ophthalmopathy?

Table of Contents

1. Report Introduction

2. Batoclimab Overview in Graves' Ophthalmopathy

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Batoclimab Market Assessment

• 5.1. Market Outlook of Batoclimab in Graves' Ophthalmopathy
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Batoclimab in the 7MM for Graves' Ophthalmopathy
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Batoclimab in the United States for Graves' Ophthalmopathy
  • 5.3.2. Market Size of Batoclimab in Germany for Graves' Ophthalmopathy
  • 5.3.3. Market Size of Batoclimab in France for Graves' Ophthalmopathy
  • 5.3.4. Market Size of Batoclimab in Italy for Graves' Ophthalmopathy
  • 5.3.5. Market Size of Batoclimab in Spain for Graves' Ophthalmopathy
  • 5.3.6. Market Size of Batoclimab in the United Kingdom for Graves' Ophthalmopathy
  • 5.3.7. Market Size of Batoclimab in Japan for Graves' Ophthalmopathy

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options